81067-82-5

Upstream product

• 35600-34-1 S-methyl isothiosemicarbazide hydroiodide 
• 100-46-9 benzylamine 
• 947748-64-3 N-2,2,5,7,8-pentamethylchroman-6-sulfonyl-N'-benzyl-N''-(tert-butoxycarbonyl)aminoguanidine 
• 44387-06-6 methyl hydrazinecarbimidothioate 
• 67-56-1 methanol 
• 79-19-6 thiosemicarbazide 
• 74-88-4 methyl iodide 
• 68695-62-5 N-benzyl-S-methyl-isothiourea 

Downstream Products

• 34103-42-9 Acetophenon-3-benzylguanylhydrazon 

Relevant academic research and scientific papers

Synthesis, Antileishmanial Activity and In Silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes

Background: Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most se-vere, fatal in 95% of cases. The undesired side-effects from first-li

KINASE INHIBITOR

The present invention aims to provide a novel kinase inhibitor and the like, and a therapeutic agent for a disease, a drug discovery screening method and the like utilizing such inhibitor and the like. The compound represented by the following formula (I) and a salt thereof can inhibit plural kinases including LATS (particularly LATS2) which is the major kinase in the Hippo signal transduction pathway. In addition, diseases or tissue damage associated with failure of cellular proliferation can be treated. Therefore, the present invention is beneficial, for example, in the research field of cell functions and diseases, in which the Hippo signal transduction pathway is involved, and the like. Furthermore, it is beneficial in the medical field for the treatment of such diseases and the like. wherein each symbol is as defined in the DESCRIPTION.

ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME

The present invention provides a medium additive composition containing a compound represented by the following formula (I), or a salt thereof: {wherein each symbol is as defined in the DESCRIPTION.}

Aminoguanidine hydrazone derivatives as non-peptide NPFF1 receptor antagonists reverse opioid induced hyperalgesia

Neuropeptide FF receptors (NPFF1R and NPFF2R) and their endogenous ligand Neuropeptide FF have been shown previously to display anti-opioid properties and to play a critical role in the adverse effects associated with chronic administrations of opiates including the development of opioid-induced hyperalgesia and analgesic tolerance. In this work, we sought to identify novel NPFF receptors ligands by focusing our interest on a series of heterocycles as rigidified non-peptide NPFF receptor ligands, starting from already described aminoguanidine hydrazones (AGH's). Binding experiments and functional assays highlighted AGH 1n and its rigidified analog 2-amino-dihydropyrimidine 22e for in vivo experiments. As earlier shown with the prototypical dipeptide antagonist RF9, both 1n and 22e reduced significantly the long lasting fentanyl-induced hyperalgesia in rodents. Altogether these data indicate that AGH rigidification maintains nanomolar affinities for both NPFF receptors, while improving antagonist character towards NPFF1R.

Synthetic routes to N-Pmc-N′,N″-disubstituted guanidines via EDCI-mediated guanylation of amines with N-Pmc-N′-substituted thioureas

An overview of the facile and high-yielding EDCI-mediated reaction of amines with N-Pmc-N′-alkyl thioureas to afford guanidines is presented, in which the general scope and limitations of the reaction are probed. It was found that the N-sulfonyl-N′-substi

Aminoguanidine derivatives

A aminoguanidine derivatives of the general formula: (wherein, R1brepresents a hydrogen atom, alkyl group of from 1 to 6 carbon atom(s), cycloalkyl group of from 5 to 7 carbon atoms or carbocyclic or heterocyclic ring unsubstituted or substitut